BlackDoctor.org3h
HIV Rates Are Dropping—But Not for Everyone. Here’s Why.
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
The American Journal of Managed Care2d
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...